### **1. Executive Summary** Mankind Pharma Limited is one of India’s largest and fastest-growing pharmaceutical companies, ranked **#4 by value** and **#2 by volume** in the Indian Pharmaceutical Market (IPM) as of FY2025. With a domestic value market share of **4.8%** (up from 4.4% in FY2024), the company has solidified its position as a market leader, primarily driven by strategic acquisitions, a robust R&D engine, digital transformation, and a growing chronic and super-specialty portfolio. The acquisition of **Bharat Serums & Vaccines Limited (BSV)** in October 2024 for **₹13,768 crore** marked a pivotal transformation, catapulting Mankind into high-entry-barrier, specialty therapy domains—particularly **women’s health, fertility, and critical care**—and making it the **#1 player in gynaecology (10.4% share)**. The company is on a deliberate journey to shift from its origins as an acute-care-focused entity toward **chronic and super-specialty therapies**, now accounting for **37.1% of revenue** in FY2025. With an **18.4% CAGR in revenue (FY21–FY25)** and strong operating metrics (adjusted EBITDA margin: **25.9%**, PAT margin: **16.4%**), Mankind is redefining Indian pharmaceutical excellence through innovation, scale, and integration. --- ### **2. Strategic Evolution & Market Positioning** #### **Founding & Growth Trajectory** - Founded in **1995** with a bottom-up strategy focused on **underserved rural and semi-urban markets**. - Expanded organically with a **pan-India footprint**, now covering over **500,000 doctors** via a field force of **~18,000 representatives**. - Entered the consumer healthcare space in **2007** with disruptive brands like **Manforce** (condoms) and **Prega News** (pregnancy tests). #### **Portfolio Diversification** - **Three Core Business Segments**: 1. **Acute & Chronic Prescription Generics** (80% of domestic revenue) 2. **Consumer Healthcare (OTC)** – ₹809 crore in FY2025, growing at **15% YoY** 3. **Super-Specialty Branded Pharmaceuticals** (post-BSV acquisition) - Strategic shift from **acute to chronic therapies**: Chronic segment revenue increased from **28% in FY18 to 37.1% in FY25**, outperforming the IPM growth by **1.3–1.4x**. - Increased penetration in **Metro and Tier I cities** via KOL engagement, hospital partnerships, and specialized divisions in cardiology, diabetology, respiratory, and neurology. #### **Leadership Benchmarks** - **#1 prescribed company in India** for 8 consecutive years; two out of every 13 prescriptions contain a Mankind product. - **#2 in Chronic Volume Market (CVM)** by volume, **#4 in IPM by value**. - Market leader in **condoms (29%), emergency contraceptives (57%), pregnancy test kits (82%)**, and **medicated anti-acne (34%)**. --- ### **3. Key Growth Levers** #### **1. Strategic Acquisitions & In-Licensing (Inorganic Growth)** - **BSV Acquisition (2024)**: - Enterprise value: **₹13,768 crore**. - Gave Mankind leadership in **women’s health, fertility, and critical care**. - Added high-margin assets: **Foligraf, Humog, Anti-D, Thymogam, ASVS**, with **limited or no competition**. - Brought a proprietary R&D platform in **recombinants, niche biologics, immunoglobulins, and complex drug delivery systems**. - BSV contributed **~₹1,723 crore revenue in FY24**, with **28% adjusted EBITDA margin**. - Enhanced global presence with operations in **15 countries**, including key markets in Philippines and Malaysia. - **Other Strategic Inorganic Moves**: - Acquired **oncology & transplant portfolio** from **Panacea Biotec**. - In-licensed **Neptaz (sacubitril/valsartan)** from **Novartis** (top 5 in heart failure). - Exclusive distribution rights for **Symbicort** (AstraZeneca) in India – entry into premium inhaler segment. - Acquired **Combihale (DRL)** for respiratory and **Daffy** for pediatric derma. - Licensed **Vonoprazan (Takeda)** for GERD and **Inclisiran (Novartis)** for lipid-lowering (launch as **Crenzlo**). #### **2. Chronic Therapy Expansion** - Revenue from chronic segment grew **12% in FY25**, driven by **insulin glargine (Nobeglar)**, **SGLT2 inhibitors (Empagliflozin)**, and **cardiac therapies**. - **Top 3 player in cardiology CVM**; anti-diabetic and respiratory portfolios growing rapidly. - In Q1 FY26, outperformed IPM by **1.5x in cardiac, 1.6x in anti-diabetic, and 1.7x in chronic therapies**. - Inhaler portfolio (Combihale + Symbicort) grew **58% YoY**, reaching ~3% market share. #### **3. Consumer Healthcare (OTC) Momentum** - OTC business generated **₹809 crore in FY2025**, up **15% YoY** after corrective measures. - Carved out into a separate wholly owned subsidiary: **Mankind Consumer Products Pvt. Ltd. (MCPL)** to unlock full potential. - Four flagship brands rank **#1 or #2 in their categories**: - **Manforce (condoms)**, **Prega News (pregnancy test)**, **Unwanted 72**, **HealthOK**, and **AcneStar**. - Strong growth in **modern trade, e-commerce, and q-commerce (77% growth in FY25)**. - New launches: **Epic ThinX (premium condoms)**, **Nimulid (pain relief)**, and **Ova News (ovulation kit)**. --- ### **4. Innovation & R&D Capabilities** Mankind is evolving into a **biopharmaceutical innovation hub** post-BSV acquisition, investing **2.2% of revenue in FY25** and targeting **2.5–3.0% by FY2026**. #### **R&D Infrastructure** - **6–7 dedicated R&D centers**, over **730 scientists** (73 PhDs). - Capabilities in **complex generics, biosimilars, biologics, and New Chemical Entities (NCEs)**. - USFDA-compliant facilities and **90+ DMF-grade APIs** launched in India. #### **Pipeline Highlights** - **MKP11093**: Best-in-class **JAK inhibitor** for autoimmune diseases (Phase 2). - **GPR119**: NCE in **Phase 2 trials** for **obesity and anti-diabetic therapy**. - **Recombinant Anti-D**: World’s first and only patented product; won **Prix Galien 2024** for innovation. - **Sintilimab**: Immunotherapy for oncology, in partnership with **Innovent Biologics**. - **Biosimilar for IVF**: First in India, in **pre-clinical stage**. - 67 **ANDAs filed in US**, 48 approved. --- ### **5. Manufacturing & Supply Chain** - **32 manufacturing facilities** across India and globally (Himachal Pradesh, Maharashtra, Rajasthan, Nepal, Germany). - **Over 75% in-house manufacturing**, enabling superior **quality control, cost efficiency, and supply chain resilience**. - **44+ billion units** of installed capacity annually. - **USFDA-approved facilities** in **India (Paonta Sahib)** and **Germany (Baesweiler)**. - **IoT and AI-driven automation** in supply chain, procurement, and warehouse management. - **Project PACE, Adapt, Wave**: Digital initiatives for end-to-end transformation. - **AI-based Sales Force Automation (SFA)** tools like **Superman** for doctor engagement. --- ### **6. International Expansion** - **13% of total revenue** from exports, growing rapidly (**100% YoY growth in FY25**). - Operates in **15 countries**, with **Philippines and Malaysia as home markets**. - Export surge driven by **BSV portfolio integration** and **niche ophthalmic and injectable products**. - Filed 67 ANDAs in the US; launched **44 products** in US market. - Partnerships: - **Insulin Aspart & Degludec** in Phase 3 with global partner. - **BSV’s recombinant platforms** used for global filings in high-barrier markets. --- ### **7. Digital & Operational Excellence** - **AI/ML Deployment**: - **Superman SFA**: AI-driven field force tool with **Nudge Engine**, **Doctor 360**, and **Share of Wallet estimation**. - **Predictive maintenance** using IoT reduced equipment downtime to **zero** across 40 critical machines. - Patient Engagement Platforms: - **Prana (chatbot)**, **Swasth 365 (disease management)**, **DrOnA Health (teleconsultation)**, **Docflix (OTT for doctors)**. - **Lean Six Sigma**: Over 300 certified practitioners; “lighthouse” plant planned with advanced automation. --- ### **8. Financial & Operational Highlights (FY25)** | **Metric** | **Value** | |----------------------------------------|--------------------------------------| | **Total Revenue (FY25)** | ₹12,207 Crore | | **Domestic Revenue (FY25)** | ₹9,866 Crore (81%) | | **Export Revenue (FY25)** | ₹1,697 Crore (13% of total) | | **OTC Revenue (FY25)** | ₹809 Crore | | **EBITDA Margin (adjusted)** | 25.9% | | **PAT Margin** | 16.4% | | **CFO/EBITDA Ratio** | ~80% | | **Net Debt/EBITDA Target** | Below 2x by FY2026 | | **Number of Brands > ₹100 Crore** | 23 | | **Top 10 Brand Families (BSV)** | 85% of BSV revenue | | **Field Force Size** | 16,500+ | | **Stockists** | >13,000 |